• Adults ​With​ ​SMA

  Novartis Announces FDA Filing Acceptance and Priority Review for AVXS-101

  Posted by michael-morale on December 4, 2018 at 9:32 am

  

  On Monday, December 3, 2018, Avexis pharmaceuticals received Priority Review Status for their drug AVXS-101 from the FDA. Priority Review Status is the same as being fast tracked, which is what happened to Biogen’s drug Spinraza when it was approved by the FDA as the first treatment for Spinal Muscular Atrophy. Upon this announcement, I produced a special edition podcast for SMA News Today and this podcast was uploaded to our multimedia accounts. Click HERE to listen to my special edition podcast.

  michael-morale replied 5 years, 4 months ago 1 Member · 0 Replies

  • avexis
  • avxs-101
  • FDA
  • SMA News Today Podcast
  • smajourney51
  • treatment
• 0 Replies

Log In to Reply